North America In Vitro Diagnostics (IVD) Market In Emerging Countries - Market Share Analysis, Industry Trends & Statistics, and Growth Forecasts 2020 - 2035
The North America In Vitro Diagnostics (IVD) Market in Emerging Countries is experiencing significant growth, fueled by technological advancements and expanding healthcare access. The market was valued at USD 4,380 Million in 2025 and is forecasted to reach USD 10,570 Million by 2035, growing at a CAGR of 9.1% between 2024 and 2035.
The economic impact of tariffs on "North America In Vitro Diagnostics (IVD) Market In Emerging Countries".
Market Growth Drivers
Expansion of Rapid Molecular Diagnostics: The expansion of rapid molecular diagnostic solutions has greatly contributed to the growth of the IVD market in North America's emerging countries. Major players like Abbott Laboratories have accelerated the deployment of portable and fast diagnostic platforms to remote and underserved communities. As infectious disease management becomes a public health priority—exemplified during the COVID-19 pandemic—the demand for point-of-care molecular IVD solutions has soared. For example, Abbott’s ID NOW platform enables COVID-19, influenza, and other infectious diseases to be tested in both clinical and decentralized settings. This has improved patient outcomes and strengthened health system resilience, especially in Mexico and the Caribbean, where accessibility used to lag.
Government Initiatives to Improve Diagnostics Infrastructure: Various governments across emerging North American countries have prioritized investment in diagnostics infrastructure. Companies such as Roche Diagnostics are benefiting from these public-private partnerships, as authorities in countries like Mexico and the Dominican Republic launch initiatives to expand laboratory networks and upgrade testing capacities for oncology, infectious, and chronic diseases. These investments have not only attracted advanced technology providers to collaborate but also improved local capabilities, driving rapid market adoption since 2020.
Market Trends
Integration of Artificial Intelligence (AI) in IVD: The adoption of AI and machine learning technologies within IVD workflows is a transformative trend. Companies such as Becton Dickinson (BD) have introduced AI-powered interpretation systems that enhance laboratory efficiency by automating result analysis. These innovations reduce human error and provide faster, more accurate results for diseases like diabetes and cancer. The trend is particularly prominent in urban centers of emerging economies in North America that are keen to modernize their healthcare infrastructure and deliver precision diagnostics.
Rise of Home-based and Digital Diagnostics: Amid changing consumer expectations and telemedicine growth, digital and home-based IVD platforms are gaining rapid adoption. For instance, Bio-Rad Laboratories recently launched digital PCR kits and user-friendly home testing solutions for metabolic and infectious diseases in Mexico and Central America. The shift toward decentralizing diagnostics reflects a greater emphasis on preventive health and personalized patient management, fundamentally changing how and where diagnostic testing occurs.
Market Opportunities
Growing Penetration in Rural Healthcare Facilities: There is a significant opportunity for IVD companies to expand into under-served rural regions in emerging North American countries. By partnering with local health authorities and NGOs, companies like Siemens Healthineers can deploy affordable, robust diagnostic technology to enhance disease detection and treatment in communities that were previously beyond the reach of modern diagnostics.
Emergence of Next-generation Diagnostic Biomarkers: Companies developing novel biomarkers for early disease detection have a substantial opportunity for growth. For example, Qiagen is investing heavily in genomic and proteomic biomarker discovery for oncology and inherited disease testing—an area with rising demand given the increasing focus on personalized medicine in emerging markets.
North America IVD Market in Emerging Countries Revenue (2020-2035)
The revenue chart indicates steady growth of the North America IVD market in emerging countries, starting at USD 2,350 Million in 2020 and steadily rising every year. A notable acceleration in growth is seen from 2025 onwards, corresponding to greater investment in diagnostic infrastructure and technology innovation. By 2035, the market is expected to more than quadruple its 2020 value, reaching USD 10,570 Million. This upward trajectory reflects increased demand for advanced diagnostic solutions, widespread healthcare reform, and the deployment of point-of-care platforms in underserved regions. The market’s compound annual growth rate of 9.1% underlines a robust expansion and signals attractive prospects for stakeholders.
IVD Market Share by Region (2025)
The 2025 market share analysis reveals Mexico as the largest contributor with 45% of the North America IVD market in emerging countries, followed by the Caribbean at 22% and Central America at 18%. Canada’s emerging regions account for 10%, while ‘Other’ countries comprise 5% of the market. The pie chart demonstrates Mexico’s prominent position as a result of higher investment and expanding healthcare programs, while the Caribbean and Central America are key growth engines due to recent improvements in laboratory infrastructure and disease screening programs. This distribution suggests concentrated but diversifying opportunity across North America’s emerging IVD landscape.
Recent Developments (Past 6 Months)
In March 2024, Roche Diagnostics announced a strategic partnership with Mexico’s Ministry of Health to deploy next-generation molecular testing systems across public hospitals and rural clinics. The agreement includes training local clinicians, improving test turnaround times, and establishing decentralized diagnostic centers targeting tuberculosis and HPV, significantly boosting Roche’s outreach in the region.
In May 2024, Abbott Laboratories rolled out its Alinity m SARS-CoV-2 Variant Assay in select Central American countries. The introduction enables rapid differentiation of COVID-19 variants, addressing the ongoing need for pandemic preparedness and surveillance. The launch was accompanied by nationwide workshops and a collaboration with local public health authorities for rapid field implementation.
In April 2024, Siemens Healthineers unveiled plans to establish a regional manufacturing hub for IVD reagents in the Dominican Republic, aiming to reduce supply chain bottlenecks and improve affordability of high-quality tests in the Caribbean and surrounding territories. The facility is projected to become operational in early 2025 and underscores Siemens’ commitment to localizing production and distribution in emerging North American markets.
Press Releases